These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7176180)

  • 1. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of 1-alpha-hydroxyvitamin D 3 treatment of osteodystrophy in uremic patients treated with periodic hemodialysis].
    Palmieri P; Albertazzi A; Cappelli P; Di Paolo B
    G Clin Med; 1981 Jul; 62(7):443-60. PubMed ID: 7308629
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis].
    Albertazzi A; Palmieri PF; Del Rosso G; Spisni C; Evangelista M
    Minerva Nefrol; 1980; 27(4):631-3. PubMed ID: 7254690
    [No Abstract]   [Full Text] [Related]  

  • 5. Cessation of bone loss in chronic renal failure by 1-alpha-hydroxyvitamin D3: a controlled trial.
    Madsen S; Olgaard K; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1978; 15():517-23. PubMed ID: 311003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of uremic osteopathy. II. Effect of 5,6-trans-25-hydroxycholecalciferol in terminal kidney insufficiency].
    von Herrath D; Kraft D; Grigoleit HG; Schaefer K
    Dtsch Med Wochenschr; 1973 Jul; 98(28):1379-81. PubMed ID: 4197778
    [No Abstract]   [Full Text] [Related]  

  • 7. Dialysis bone disease in childhood: treatment with 25-hydroxycholecalciferol.
    Luciani JC; Meunier PJ; Dumas R
    Pediatr Res; 1979 Oct; 13(10):1105-8. PubMed ID: 503634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
    Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D
    Bone; 1992; 13(5):369-77. PubMed ID: 1419378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone maturation in children with chronic renal failure. Effect of 1 alpha-hydroxy vitamin D3 and renal transplantation.
    Johannsen A; Nielsen HE; Hansen HE
    Acta Radiol Diagn (Stockh); 1979; 20(1):193-9. PubMed ID: 377915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical investigation of 1 alpha-OH-D3 on hemodialyzed patients.
    Watanabe Y; Asai K; Okura T; Kawahara H; Sakamoto N
    Nagoya J Med Sci; 1982 Mar; 44(3-4):89-101. PubMed ID: 7110306
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of calcifediol in renal osteodystrophy.
    Recker R; Schoenfeld P; Letteri J; Slatopolsky E; Goldsmith R; Brickman A
    Arch Intern Med; 1978 May; 138 Spec No():857-63. PubMed ID: 646574
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effects of CaCO3 on renal osteodystrophy--comparison of patients with chronic renal failure in the predialytic stage and patients undergoing maintenance hemodialysis].
    Okada K; Kuno T; Yanai M; Maeda H; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1988 Aug; 30(8):1053-62. PubMed ID: 3244188
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effects of estrogen on renal osteodystrophy in the female patients undergoing maintenance hemodialysis].
    Akino H; Saito A; Maeda S; Kitajima W; Okano M; Isomatsu Y; Muranaka K; Kanimoto Y; Shimizu Y; Kawada Y
    Nihon Jinzo Gakkai Shi; 1986 Aug; 28(8):1129-36. PubMed ID: 3807045
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized double blind study of 1, 25(OH)2D3 in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC; Kleit SA
    Proc Clin Dial Transplant Forum; 1977; 7():166-9. PubMed ID: 210446
    [No Abstract]   [Full Text] [Related]  

  • 16. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications].
    García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F
    Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) and eel calcitonin derivative in experimental renal osteodystrophy].
    Minatoguchi T
    Nihon Jinzo Gakkai Shi; 1982 Oct; 24(10):1157-71. PubMed ID: 7161947
    [No Abstract]   [Full Text] [Related]  

  • 19. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of uremic osteodystrophy].
    Fletti C; Docci D; Coli' L; Di Felice A
    G Clin Med; 1981 Apr; 62(4):270-9. PubMed ID: 7021295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.